Skip to content

Released Nov 12, 2024, before the open

10-Q filed Nov 12, 2024, 43 days after period end · 0001171843-24-006248

Q3 2024 · 10-Q
Revenue$0.00— vs Q3 2023−100.0% vs Q2 2024
Net Income-$10.48MN/M vs Q3 2023N/M vs Q2 2024
EPS, diluted—
Operating Income-$12,239,000N/M
Operating Cash Flowderived-$11,051,000N/M
Free Cash Flowderived-$11,095,000N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$0.00$0.00——
Net Income-$10.48M-$9.96M-$11.98M-$5.98M
EPS Diluted———-$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR